Kinea Bio

Executive Summary

Kinea Bio is a private biotechnology company founded in 2020 and headquartered in Cambridge, MA, focused on developing next-generation genetic medicines for severe neuromuscular disorders. Leveraging proprietary platform technologies, the company aims to overcome key limitations of current gene therapies by enabling delivery of larger therapeutic proteins, achieving optimal tissue-specific expression, and allowing for repeat dosing. With its lead program in Phase 2, Kinea Bio is positioned to address significant unmet needs in neuromuscular diseases, where existing gene therapies are limited by payload capacity, immunogenicity, and durability challenges. The company's platform is designed to broaden the applicability of gene therapy to a wider range of patients and indications.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 data readout for lead neuromuscular program60% success
• Q1 2026IND filing for second program in neuromuscular disease70% success
• Q2 2026Potential partnership or licensing deal for platform technology40% success